Previous 10 | Next 10 |
Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today a...
Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) (Paris:NANO) (NASDAQ:NBTX) , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for pa...
Data to be presented at the 36 th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC) Data show radiotherapy-activated NBTXR3 increased CD8+ T cell infiltration and modulated the T cell receptor repertoire in a mouse model, suggesting stronger immune...
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority) Regulatory News: Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Eurone...
Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘ Company ’’) , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today a...
Data presented by Professor Christophe Le Tourneau at the 2021 Annual Meeting of the American Society for Radiation Oncology First survival data from Phase I Dose Expansion in tough-to-treat elderly and frail LA-HNSCC patients ineligible for cisplatin and intolerant to cetuxim...
Published preclinical data in Red Journal supporting the hypothesis that NBTXR3 activated by radiotherapy in combination with anti-PD-1 could effectively control primary and metastatic tumors, evoke abscopal effect, and reduce the possibility of developing distant lung metastases ...
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority) Regulatory News: Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Eurone...
Poster presentation by Pr. Christophe Le Tourneau featuring first OS and PFS data from phase I expansion study of NBTXR3 as a single agent activated by radiotherapy in tough-to-treat HNSCC population Oral presentation by Dr. Tanguy Y. Seiwert with comprehensive review of local and...
Data Published in the November 2021 Edition of the International Journal of Radiation Oncology, Biology, Physics (Red Journal) Study hypothesized that NBTXR3 in combination with radiotherapy and anti-PD-1 could transform irradiated tumors into “self-vaccinesȁ...
News, Short Squeeze, Breakout and More Instantly...
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities...
Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment 48% ORR in evaluable anti-PD-1 naïve patients (n=25...
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck cancer (n=68) to be presented by Coordinating Investigator Colette Shen, MD, PhD, a...